Cipla Limited (CIPLA.NS) : juste valeur

Thèse ACCE

Cipla makes generic and specialty drugs across respiratory (inhalers and nebulised products), HIV antiretrovirals, oncology and complex injectables, with a large US generics franchise and a dominant position in Indian branded formulations. Its edge is scale in hard-to-make products: inhalation and complex generics have fewer competitors than oral tablets, which helps sustain a 63.3% gross margin even though operating margin sits at 12.5%, the gap reflecting heavy R&D and selling spend. Revenue growth of 3.5% is subdued, so the near-term case rests on margin recovery and new launches in US specialty and respiratory lines rather than volume expansion. At 31.9x trailing earnings against 21.0x forward, the market is pricing in a sizeable earnings rebound, which makes the thesis hinge on whether margins can improve from here. It is worth a deeper look if you want exposure to Indian pharma's US generics pipeline and are comfortable with that margin-recovery bet, but the top-line growth rate is the figure to test first.